Pitfalls in Gallium-68 PSMA PET/CT Interpretation—A Pictorial Review
Open Access
- 1 December 2018
- journal article
- review article
- Published by MDPI AG in Tomography
- Vol. 4 (4), 182-193
- https://doi.org/10.18383/j.tom.2018.00021
Abstract
The novel Gallium-68 prostate-specific membrane antigen (PSMA)-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-diacetic acid positron emission tomography (PET) tracer is increasingly used in the evaluation of prostate cancer, particularly in the detection of recurrent disease. However, PSMA is expressed in nonprostatic tissues, as well as in other pathologic conditions. Here we illustrate such interpretive pitfalls with relevant images that one may encounter while reporting PSMA PET/CT. This study aims to show variation in physiological distribution of PSMA activity and uptake in various benign and neoplastic disorders that may be misinterpreted as prostatic metastatic disease. These pitfalls are illustrated to enhance awareness, aiding a more accurate interpretation of the study. Retrospective database of all (68) Ga PSMA PET/CT was created and reviewed. In total, 1115 PSMA PET/CT studies performed between February 27, 2015, and May 31, 2017, were reviewed. Any unusual uptake of PSMA was documented, described, and followed up. All cases were then subdivided into the following 4 categories: physiological uptake, benign pathological uptake, nonprostatic neoplastic uptake, and miscellaneous uptake. A variety of nonprostatic tissues and lesions, including accessory salivary gland, celiac ganglion, gall bladder, Paget's bone disease, reactive lymph nodes, non-small cell lung cancer, renal cell cancer, and neuroendocrine tumor, were found to show PSMA uptake. PSMA uptake is not prostate-specific and can be taken up physiologically and pathologically in nonprostatic tissue. It is important for reporting physicians to recognize these findings and instigate appropriate investigations when required while avoiding unnecessary procedures in physiological variation.Keywords
This publication has 36 references indexed in Scilit:
- Gallium-68 Prostate-Specific Membrane Antigen PET ImagingPET Clinics, 2017
- Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical ProstatectomyJournal of Nuclear Medicine, 2015
- The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Hybrid Positron Emission Tomography–Magnetic Resonance Imaging with Gallium 68 Prostate-specific Membrane Antigen Tracer: A Next Step for Imaging of Recurrent Prostate Cancer—Preliminary ResultsEuropean Urology, 2013
- Molecular Imaging of Prostate Cancer with PETJournal of Nuclear Medicine, 2013
- PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane AntigenCurrent Topics in Medicinal Chemistry, 2013
- 11C-Choline PET/CT and PSA kineticsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Radionuclide and hybrid imaging of recurrent prostate cancerThe Lancet Oncology, 2010
- Management of recurrent disease after radical prostatectomyProstate Cancer and Prostatic Diseases, 2004